ArriVent BioPharma, Inc. (AVBP) vs Design Therapeutics, Inc. (DSGN)
A side-by-side comparison of ArriVent BioPharma, Inc. and Design Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$15.09HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
DSGN
Design Therapeutics, Inc.
$11.97HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — AVBP vs DSGN
growth of $100 · dividends reinvested · last 3yAVBP +42.3% (+12.5%/yr)DSGN +426.3% (+73.9%/yr)DSGN compounded faster over this window
AVBP DSGN
AVBP vs DSGN: by the numbers
- •DSGN is the larger company ($748M vs $703M market cap).
Metrics side by side
Valuation
| Metric | AVBP | DSGN |
|---|---|---|
| P/B ratio | 1.92 | 3.70 |
Profitability
| Metric | AVBP | DSGN |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -44.63% | -35.07% |
| ROIC | -47.96% | -38.92% |
Growth (annualized)
| Metric | AVBP | DSGN |
|---|---|---|
| Total return CAGR (5Y) | N/A | -3.82% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.